Geiken-Weinstock, R.; Griesinger, F.; Metz, M.; Meyer, R.G.; Staib, P.; Overbeck, T.; Goeken, N.; Hübner, J.; Bäsecke, J.
Delay of Systemic Therapy Confers a Survival Benefit in Patients with Stage IV Non-Small-Cell Lung Cancer. Cancers 2025, 17, 3531.
https://doi.org/10.3390/cancers17213531
AMA Style
Geiken-Weinstock R, Griesinger F, Metz M, Meyer RG, Staib P, Overbeck T, Goeken N, Hübner J, Bäsecke J.
Delay of Systemic Therapy Confers a Survival Benefit in Patients with Stage IV Non-Small-Cell Lung Cancer. Cancers. 2025; 17(21):3531.
https://doi.org/10.3390/cancers17213531
Chicago/Turabian Style
Geiken-Weinstock, Rike, Frank Griesinger, Michael Metz, Ralf Georg Meyer, Peter Staib, Tobias Overbeck, Nils Goeken, Joachim Hübner, and Jörg Bäsecke.
2025. "Delay of Systemic Therapy Confers a Survival Benefit in Patients with Stage IV Non-Small-Cell Lung Cancer" Cancers 17, no. 21: 3531.
https://doi.org/10.3390/cancers17213531
APA Style
Geiken-Weinstock, R., Griesinger, F., Metz, M., Meyer, R. G., Staib, P., Overbeck, T., Goeken, N., Hübner, J., & Bäsecke, J.
(2025). Delay of Systemic Therapy Confers a Survival Benefit in Patients with Stage IV Non-Small-Cell Lung Cancer. Cancers, 17(21), 3531.
https://doi.org/10.3390/cancers17213531
